HEXABRIX
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEXABRIX is an injectable small-molecule contrast agent approved in 1985 for radiographic imaging procedures. The product is a diagnostic agent used to enhance visualization during medical imaging studies. It belongs to the contrast media category used primarily in angiographic and other imaging applications.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting defensive positioning and focus on retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HEXABRIX currently shows zero linked job openings, reflecting its mature lifecycle stage and stable market position. Career opportunities are limited to defensive roles focused on market maintenance, pricing strategy, and regulatory compliance rather than growth initiatives.
Product ManagerSales Representative
Worked on HEXABRIX at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.